BOSTON — The Massachusetts attorney general’s office is investigating whether the makers of a breakthrough treatment for hepatitis C are violating state law by pricing the drug too high.
Attorney General Maura Healey on Wednesday released a letter sent to the chief executive of California-based Gilead Sciences Inc. In it, Healey said her office was examining whether the pricing constituted an unfair trade practice.
Sovaldi was the company’s first hepatitis C drug. It was priced at $1,000 per pill in the U.S., or $84,000 for a course of treatment. It has since introduced Harvoni, a more expensive, next-generation pill.
Healey urged Gilead to adjust its pricing to make the treatments more accessible.
The company says it had requested a meeting with Healey and agrees with the importance of helping all patients.
